C07C233/15

PROCESSES FOR PREPARATION OF 4-AMINOINDANE DERIVATIVES AND RELATED AMINOINDANE AMIDES

A process for preparation of 4-aminoindane derivatives of a first formula, salts and enantiomers thereof comprising the steps of: a) hydrogenating a 1,2-dihydroquinoline of a second formula to give a corresponding tetrahydroquinoline of a third formula; b) acylating the tetrahydroquinoline of the third formula with a carboxylic acid derivative of a fourth formula to obtain a corresponding acyl derivative compound of a fifth formula; c) rearranging the acyl derivative compound of the fifth formula under acidic conditions so as to give an acyl indane compound of a sixth formula; and d) hydrolysing the acyl group of the acyl indane compound of the sixth formula so as to obtain the 4-aminoindane derivatives of the first formula.

ANALGESIC COMPOUNDS

Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.

Process for preparing biphenylamines from anilides by ruthenium catalysis

The present invention relates to a novel process for preparing substituted biphenylamides of the general formula (V) ##STR00001##
characterized in that
anilides of the formula (II) ##STR00002##
in a solvent other than tetrahydrofuran,
are reacted with an organoboron compound of the formula (III) ##STR00003##
in the presence of a catalyst system consisting of a ruthenium catalyst, an activator, an oxidizing agent and a metal triflate.

Process for preparing biphenylamines from anilides by ruthenium catalysis

The present invention relates to a novel process for preparing substituted biphenylamides of the general formula (V) ##STR00001##
characterized in that
anilides of the formula (II) ##STR00002##
in a solvent other than tetrahydrofuran,
are reacted with an organoboron compound of the formula (III) ##STR00003##
in the presence of a catalyst system consisting of a ruthenium catalyst, an activator, an oxidizing agent and a metal triflate.

Process for preparing biphenylamines from anilides by ruthenium catalysis

The present invention relates to a novel process for preparing substituted biphenylamides of the general formula (V) ##STR00001## characterized in that anilides of the formula (II) ##STR00002## in a solvent other than tetrahydrofuran, are reacted with an organoboron compound of the formula (III) ##STR00003## in the presence of a catalyst system consisting of a ruthenium catalyst, an activator, an oxidizing agent and a metal triflate.

Process for preparing biphenylamines from anilides by ruthenium catalysis

The present invention relates to a novel process for preparing substituted biphenylamides of the general formula (V) ##STR00001## characterized in that anilides of the formula (II) ##STR00002## in a solvent other than tetrahydrofuran, are reacted with an organoboron compound of the formula (III) ##STR00003## in the presence of a catalyst system consisting of a ruthenium catalyst, an activator, an oxidizing agent and a metal triflate.

PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM
20190092716 · 2019-03-28 ·

The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative.

PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM
20190092716 · 2019-03-28 ·

The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative.

PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORM
20190092716 · 2019-03-28 ·

The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative.

IMMUNOREGULATORY AGENTS

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.